Azupentat - General Information
A methylxanthine derivative that inhibits phosphodiesterase and affects blood rheology. It improves blood flow by increasing erythrocyte and leukocyte flexibility. It also inhibits platelet aggregation. Azupentat modulates immunologic activity by stimulating cytokine production.
Pharmacology of Azupentat
Azupentat, a synthetic dimethylxanthine derivative structurally related to theophylline and caffeine, is used in the treatment of peripheral vascular diseases and in the management of cerebrovascular insufficiency, sickle cell disease, and diabetic neuropathy.
Azupentat for patients
Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with TRENTAL with and without anticoagulants or platelet aggregation inhibitors. Patients on Warfarin should have more frequent monitoring of prothrombin times, while patients with other risk factors complicated by hemorrhage (e.g., recent surgery, peptic ulceration) should have periodic examinations for bleeding including hematocrit and/or hemoglobin. Concomitant administration of TRENTAL and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals. Such patients should be closely monitored for signs of toxicity and have their theophylline dosage adjusted as necessary. TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. Small decreases in blood pressure have been observed in some patients treated with TRENTAL; periodic systemic blood pressure monitoring is recommended for patients receiving concomitant antihypertensive therapy. If indicated, dosage of the antihypertensive agents should be reduced.
No information provided.
Additional information about Azupentat
Azupentat Indication: For the treatment of patients with intermittent lameness or immobility arising from chronic occlusive arterial disease of the limbs.
Mechanism Of Action: Azupentat inhibits erythrocyte phosphodiesterase, resulting in an increase in erythrocyte cAMP activity. Subsequently, the erythrocyte membrane becomes more resistant to deformity. Along with erythrocyte activity, pentoxifylline also decreases blood viscosity by reducing plasma fibrinogen concentrations and increasing fibrinolytic activity.
Drug Interactions: Aminophylline Azupentat increases the effect and toxicity of theophylline
Dyphylline Azupentat increases the effect and toxicity of theophylline
Theophylline Azupentat increases the effect and toxicity of theophylline
Oxtriphylline Azupentat increases the effect and toxicity of theophylline
Anisindione Azupentat increases the anticoagulant effect
Dicumarol Azupentat increases the anticoagulant effect
Acenocoumarol Azupentat increases the anticoagulant effect
Warfarin Azupentat increases the anticoagulant effect
Food Interactions: Not Available
Generic Name: Pentoxifylline
Synonyms: Not Available
Drug Category: Free Radical Scavengers; Vasodilator Agents; Radiation-Protective Agents; Hematologic Agents; Hemorrheologic Agents
Drug Type: Small Molecule; Approved
Other Brand Names containing Pentoxifylline: Azupentat; Dimethyloxohexylxanthine; Durapental; Oxpentifylline; PENTOXYPHYLINE; Pentoxifyllin; Pentoxil; Pentoxiphyllium; Pentoxyfylline; Pentoxyphylline; Rentylin; Torental; Trental; Vazofirin;
Absorption: Not Available
Toxicity (Overdose): LD50=1385 mg/kg(orally in mice)
Protein Binding: 70%
Biotransformation: Not Available
Half Life: 0.4-0.8 hours
Dosage Forms of Azupentat: Tablet, extended release Oral
Chemical IUPAC Name: 3,7-dimethyl-1-(5-oxohexyl)purine-2,6-dione
Chemical Formula: C13H18N4O3
Pentoxifylline on Wikipedia: http://en.wikipedia.org/wiki/Pentoxifylline
Organisms Affected: Humans and other mammals